Net income came in at approximately $28,000,000 and diluted EPS was $0.46 on 62,000,000 shares. Looking at our GAAP results, operating expenses declined by approximately $4,000,000 from the prior quarter due to a $5,000,000 gain from a change in estimate related to the Epi Luvac acquisition. Now moving to the balance sheet and cash flow highlights. We ended the quarter with cash and short term investments of $321,000,000 a sequential increase of $16,000,000 From a working capital perspective, our accounts receivable increased by $40,000,000 to $132,000,000 primarily due to timing of shipments as well as a change in customer mix. Inventory decreased by $3,000,000 to $242,000,000 and accounts payable increased by $3,000,000 to $50,000,000 Customer deposits included within contract liabilities on the balance sheet increased by $1,000,000 to $60,000,000 Cash flow from operations came in at $18,000,000 and CapEx $4,000,000 Turning to our Q4 and full year 2024 outlook.